The global nanofluidics market is surging, with an overall revenue growth expectation of hundreds of millions of dollars over the forecast period from 2023 to 2032.
The study of fluids contained in structures with nanometric dimensions (usually 1–100 nm) is known as nanofluidics. Because of the high surface-to-bulk ratio, fluids contained in these structures show behaviors that are not seen in bigger structures. Technically speaking, nanofluidics is not a new area of study and has existed implicitly in many fields, but it has only lately been given a name of its own. Recent technological advancements have made it feasible to influence what happens at these scales, which has led to this evolution.
Additionally, improvements in observation and measurement methods now make it possible to measure the minute physical quantities that are peculiar to nanoscale systems. It would be erroneous to view nanofluidics as an extension of microfluidics, despite the fact that it was born in the wake of microfluidics. In fact, whereas in microfluidics the only scale that matters is the system size, in nanofluidics a wide range of characteristic lengths that produce coupled phenomena and give rise to complicated fluid behaviors must be taken into account.
Furthermore, because nanofluidics is at the convergence of physics, chemistry, and biology, it has implications for a wide range of fields, including physiology, membrane science, thermodynamics, and colloidal science. Consequently, nanofluidics research frequently requires an interdisciplinary approach.
The market growth is being driven by various factors such as growing investment in nanotechnology across the industry, increasing cases of cancer across the globe, growing pharmaceutical and biotechnology industry, and growing adoption of nanofluidics platforms for immunotherapy.
Report Scope of the Nanofluidics Market:
|Largest Market||North America|
|Fastest Growing Market||Asia Pacific|
|Forecast Period||2023 to 2032|
|Segments Covered||By Product Type, By Application, and By Material|
|Regions Covered||North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa|
Growing prevalence of cancer across the globe
The growing prevalence of cancer across the globe is expected to drive the growth of the market over the forecast period. For cell biology, disease pathology, drug development, and medical treatment, living single-cell investigation is essential. Finding the law of the universe and learning how serious diseases occur are very important. To obtain the average information about cells, the traditional single analysis concentrates on a large number of cells or cell lysis.
As a result, it is unable to assess the ongoing, real-time data on variations between individual cells, which restricts the growth of numerous industries, including the biomedical one. Small sample volumes, quick turnaround times, easy operation, and efficient processing, which have been widely used in complex operations like single cell capture, separation, and detection, distinguish nanofluidics-based biochemical analysis from conventional methods. Thus, the increasing incidence of cancer is anticipated to drive the demand for nanofluidics.
For instance, according to the International Agency for Research on Cancer, one of the main causes of death in the globe is cancer. In 2018, there were 18.1 million new instances of cancer and 9.5 million cancer-related deaths worldwide. By 2040, it is predicted that there will be 29.5 million new cases of cancer per year and 16.4 million cancer-related deaths.
Stability of nanofluids
The stability of nanofluids is one of the major drawbacks that hinder market growth over the forecast period. Nanofluids lose their capacity to conduct heat because of their propensity to aggregate. For the evaluation of nanofluids that can alter their thermophysical properties for applications, their stability is a crucial factor. Utilizing physical (ultrasonic agitation, homogenization, and ball milling) and chemical (surfactant addition, surface modification, and pH correction) methods, the long-term stability and thermal properties of the nanofluids were improved. Thus, during the projection period, the stability of nanofluids may be impeding market expansion.
The growing application of nanofluidics in immunotherapy
A newer form of treatment called immunotherapy strengthens the body's natural defenses against diseases like cancer. Cell-based therapeutics, cancer vaccines, and monoclonal antibodies checkpoint inhibitors are the three main categories of cancer immunotherapy. Engineered T cells and nanoscale extracellular vesicles are frequently used in cell-based immunotherapy and tailored therapeutics as a result of advancements in biotechnology and a better understanding of immune oncology.
As cutting-edge tools for cell/EV engineering, single-cell manipulation and analysis, as well as the investigation of the tumor microenvironment, microfluidics and nanofluidics platforms uniquely provide advantages. Thus, the growing adoption of nanotechnology in immunotherapy is expected to offer an enormous opportunity for market expansion during the forecast period.
Product Type Insights:
Based on the product type, the global nanofluidics market is segmented into nanofluidic-based devices, nanofluidic components, and others. The nanofluidics component is expected to dominate the market during the forecast period. The nanofluidics segment is further classified into nanofluidic chips, nano pumps, nanoneedles and others. Nanofluidic chips are expected to grow at a significant rate during the forecast period.
The use of nanofluidic chips enables the study of nanofluids under a variety of flow conditions with little to no pressure shockwave interference and no viewing window distortion. Thus, owing to these properties of the nanofluidics chip system are expected to drive the growth of the market over the forecast period. Nanopumps is expected to grow at the fastest rate over the forecast period. The growth in the segment is owing to the use of these devices to detect DNA sequencing. A tool for locating a target nucleic acid sequence contained in a mixture of nucleic acid fragments and having a chosen pH is also included in the invention. Thus, this is expected to drive the segmental growth during the forecast period.
Based on the application, the global nanofluidics market is divided into drug delivery, point-of-care diagnostics, pharmaceutical and biotechnology research, clinical diagnostics and others. The point-of-care diagnostics is expected to grow at the highest CAGR over the forecast period. Through the combined impact of effective mass transfer and low diffusion distances, protein sensing in a nanofluidic environment drastically reduces the time it takes for an immunoassay to provide a result.
The use of in vitro diagnostic (IVD) testing at the point of care is spreading among medical practitioners worldwide. In fact, compared to laboratory tests, their quick turnaround times allow for quicker disease diagnosis, monitoring, and clinical management decisions.
This significant advantage makes them particularly helpful in clinical emergencies, such as acute heart failure and myocardial infarction, acute respiratory illness, and septic shock. However, the advantage of utilizing near-patient environmental conditions and on-the-spot biomarker measurement to speed up clinical decision-making is only valid if technical, analytical, and diagnostic performances are comparable to those of the equivalent tests carried out in a controlled laboratory setting. Thus, this factor drives the segment growth during the forecast period.
North America is expected to capture the largest market share over the forecast period. The growth in the region is attributed to the growing pharmaceutical and biotechnology industry. For instance, according to the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA), it is estimated that the US bioscience industry was valued at 2.9 trillion dollars in 2021. In addition, they also revealed that the US industry employed 2.1 million people in over 127,000 businesses. Moreover, the increasing R&D for proteomics research in the region also provides an enormous opportunity for market expansion. For instance, in July 2021, the United States NIH invested around USD 20 million in technology development in single-molecule and single-cell proteomics.
This increases the research activities on proteomics in the country, in turn, penetrates the market. Furthermore, the robust healthcare infrastructure and the growing use of the nanofluidic system for cancer research are expected to propel the market. The cancer cases in the region are very high including lung cancer, pancreatic cancer, breast cancer and others. According to a recent analysis of data from the National Program of Cancer Registries database, which includes information on about 65% of the US population, the incidence of pancreatic cancer is rising more quickly in women than in men under the age of 55 and among people 55 and older.
The Asia Pacific is expected to grow at the fastest rate during the forecast period. The regional growth is attributed to the growing government initiatives and the growing incidence of chronic diseases such as cardiovascular, cancer, and others. For instance, in rural and urban areas, respectively, cardiovascular disease (CVD) caused 46.74% and 44.26% of all fatalities in 2019. CVD was the cause of two out of every five fatalities. In China, there are thought to be 330 million CVD patients.
The incidence of pancreatic cancer in India is also 0.5-2.4 per 100,000 men and 0.2-1.8 per 100,000 women, according to the secondary analysis. Furthermore, the increasing healthcare industry in the region is one of the key factors that propel the market growth during the study period.
Key Market Players:
Segments Covered in the Report:
(Note*: We offer report based on sub segments as well. Kindly, let us know if you are interested)
By Product Type
No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client